CLX

Business profile & competitive position

The Clorox Company operates in the Consumer Defensive sector, specifically the Household & Personal Products industry, manufacturing and marketing a稳定 of consumer and professional brands. Its portfolio includes household names such as Clorox, Pine-Sol, Glad, Fresh Step, Kingsford, Hidden Valley, Brita, and Burt’s Bees, while its professional business sells Purell, CloroxPro, and Clorox Healthcare. According to its most recent 10-K, Clorox generated fiscal 2026 net sales of $6.7 billion, employed roughly 9,200 people, operated in approximately 25 countries, and sold products in about 95 markets.

The reported net margin of 8.7% supports the idea that Clorox can convert revenue into profit at a reasonable level for a branded staples business. The ROE figure of -1893.5%, however, is so extreme that it effectively signals negative or distorted book equity rather than an operating failure. In practice, a negative ROE of that magnitude usually reflects a capital structure where liabilities exceed assets on the balance sheet, which can follow sizeable buybacks, write-downs, or accounting adjustments. For evaluating competitive moat here, the more reliable signal is brand durability and shelf presence, evidenced by the fact that Walmart alone accounted for 26% of consolidated FY2026 net sales and the five largest customers represented about half of consolidated net sales. That concentration is a double-edged sword: it confirms distribution power, but it also gives a handful of retailers outsized bargaining leverage.

Financial posture

As of the current snapshot, Clorox carried a market capitalization of $12.9 billion and traded at a price-to-earnings ratio of 22.1. The net margin of 8.7% is consistent with a mature consumer staples business, while the beta of 0.54 indicates the stock has historically moved roughly half as much as the broad market, fitting its defensive classification. The stock price was $106.69 with a 50-day exponential moving average of $100.74 and an RSI of 60.1, meaning it had moved from below to modestly above short-term trend momentum without being technically stretched.

The standout anomaly in the financial posture is the ROE of -1893.5%. Because ROE is net income divided by shareholders’ equity, a figure this negative implies book equity is close to zero or negative while net income remains positive. Investors looking at classic return-on-equity screens should treat this metric with caution for Clorox and focus instead on free cash flow, gross margins, and the stability of branded cash flows. The P/E of 22.1 sits in a range that neither screams distress nor implies a deep discount relative to many staples peers, especially given that fiscal 2026 saw diluted EPS decline 26%.

Strategic priorities & outlook

Clorox’s most recent 10-K outlines an operational agenda built around the IGNITE strategy. The four stated choices are: fueling long-term profitable growth, innovating consumer experiences, reimagining how the company and its people work, and continuously evolving the product portfolio. Those are not merely marketing lines; they are tied to specific, ongoing investments such as the rollout of a new enterprise resource planning (ERP) system and a broader digital transformation intended to create long-term efficiencies across supply chain, digital commerce, innovation, and brand building.

The company is also explicitly prioritizing a streamlined operating model, stronger digital capabilities, and health-and-hygiene expansion. The April 2026 completion of the GOJO Industries acquisition is a concrete example of the latter, expanding the health and hygiene portfolio and strengthening Clorox’s business-to-business presence through Purell and related professional lines. Integrating GOJO and growing the professional and institutional markets will likely absorb management bandwidth over the coming quarters. Another operational detail that matters is the January 31, 2026 expiration of the Glad bags and wraps venture with Procter & Gamble, after which Clorox purchased P&G’s 20% interest and retained core intellectual property licenses on a royalty-free basis. That simplifies ownership of Glad but removes P&G as a partner, so execution now rests entirely with Clorox.

Macro & geopolitical exposure

As a Consumer Defensive / Household & Personal Products company, Clorox is generally considered a staples business with relatively inelastic demand for cleaning supplies, charcoal, trash bags, and personal-care products. Still, the industry carries real macro and geopolitical sensitivities. Raw materials, including chemicals, plastic resins, paper pulp, and packaging, are exposed to commodity-price swings. Transportation, warehousing, and supply-chain costs can move with fuel prices and labor availability, and imports of materials or finished goods can be affected by tariffs, trade policy, and port congestion.

Currency translation is another factor: sales generated outside the U.S. flow back at fluctuating exchange rates, and Clorox sells in roughly 95 markets. Regulatory exposure is material as well, because disinfectants, health products, food-contact items, and personal-care formulations are overseen by agencies such as the Environmental Protection Agency and the Food and Drug Administration. Label, safety, and environmental rules can change compliance costs quickly. Finally, private-label competition tends to intensify when consumers trade down during periods of economic stress, which can pressure branded pricing power even in defensive categories.

Recent developments

Recent news flow has centered on institutional accumulation and the GOJO integration. On August 24, 2026, defenseworld.net reported that Barrow Hanley Mewhinney & Strauss LLC acquired 106,377 shares in Clorox. The same day, Bank of New York Mellon Corp disclosed a new $123.15 million investment in the company. Earlier in the week, on August 22, 2026, defenseworld.net noted that BlackRock Inc. acquired 10,044,423 shares. On August 21, 2026, zacks.com published an article titled “How GOJO Could Shape Clorox's Fiscal 2027 Growth and Margin Outlook,” underscoring that analysts are focused on how quickly the acquisition can contribute to sales and profitability.

Headlines about institutional buying do not determine a stock’s future direction, but they do show that several large asset managers have recently allocated capital to the name. The concentration of these filings within a single week in late August 2026 has made GOJO’s integration, fiscal 2027 guidance, and margin trajectory the central narrative heading into the next earnings report.

Earnings behavior & post-earnings drift

Clorox has beaten earnings expectations in 6 of the last 8 reported quarters, a 75% beat rate, with an average earnings surprise of 9.4%. The average 5-day price move after earnings across those quarters has been +1.67%, classified as an “up” drift. That pattern suggests the stock has historically tended to absorb positive surprise and carry some follow-through momentum in the days after reports, though individual quarters have varied sharply.

The most recent four quarters illustrate that variability. On August 3, 2026, Clorox reported EPS of $1.66 against an estimate of $1.64, a 1.2% beat, and the stock rose 6.52% the next day and 9.61% over the following five trading days. On April 30, 2026, EPS of $1.64 beat the $1.55 estimate by 5.8%, yet the stock fell 9.67% the next day and 4.49% over five days, a reminder that the headline beat/miss does not always dictate price action. The February 3, 2026 quarter was a miss: EPS of $1.39 versus the $1.43 estimate, a -2.8% surprise, but the stock still rose 2.43% the next day and 5.63% over five days. The November 3, 2025 quarter showed a 3.9% beat ($0.85 versus $0.818), yet the five-day drift was -4.08% despite a modest next-day gain. The next scheduled earnings release is November 3, 2026, after the market close, with the current consensus EPS estimate at $1.11.

For investors trying to weigh Clorox's defensive cash-flow profile against its ERP-transition expenses and GOJO integration risk, the next earnings report on November 3, 2026 will be a useful cross-check against the current $1.11 consensus. To go deeper into how institutional analysts are modeling the company’s margin trajectory and valuation, consider reviewing the full institutional verdict on CLX.